• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

    2/26/25 3:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email
    • 7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.
    • 18% of couples reported sleeping in separate rooms due to snoring and restlessness.
    • Women report fewer quality sleep nights and more difficulties falling asleep than men.

    SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)), a global health technology leader focused on sleep, breathing, and care delivered in the home, today unveiled the findings of its fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscores a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep each week.

    Despite a trend towards growing awareness of sleep's importance, many continue to suffer in silence and remain trapped in a cycle of exhaustion. The research reveals that nearly one in four (22%) respondents choose to just live with poor sleep rather than seek help. With poor sleep found to impact our lives, from work1, to relationships2, and mental health, there is an urgent need for increased awareness and action on sleep health.

    A World Without Rest

    About one-third of survey respondents report difficulty falling or staying asleep three or more times per week, citing stress (57%), anxiety (46%), and financial pressures (31%) as primary disruptors. While well-rested individuals experience improved mood, concentration, and productivity, those struggling with poor sleep report excessive daytime sleepiness, irritability, and difficulty concentrating. Yet few take proactive steps to improve their sleep health:

    • 89% of respondents believe sleep makes them feel better about themselves, but only 24% would take immediate action to address sleep issues.

    • 22% globally, and up to 41% in Australia, chose to "just live with" poor sleep.

    • 45% do not track their sleep, missing valuable insights that could improve sleep quality.

    "Sleep is as vital to health as diet and exercise, yet millions struggle in silence," said Carlos M. Nunez, M.D., ResMed's Chief Medical Officer. "This research highlights an urgent gap in awareness and action—one that needs immediate attention, to improve global health outcomes."

    Poor Sleep: The Hidden Drain on Workplace Productivity

    Quality sleep directly impacts workplace performance, but many employees struggle due to sleep deprivation:

    • A staggering 71% of employed respondents globally have called in sick due to poor sleep at least once in their career, with the highest rates in India (94%), followed by China (78%), Singapore (73%), and the U.S. (70%).

    • Nearly half (47%) of the workforce surveyed feel that their sleep health isn't a priority for their employers, presenting an opportunity for employer initiatives to encourage healthy sleep habits.

    Bedtime Blues: Sleep Impacts Relationships

    Responses from the survey suggest that sleep may play an important role in the health of our relationships:

    • 18% of couples permanently opt for a "sleep divorce," choosing to sleep apart due to snoring and restlessness.

    • Among those who sleep separately, 31% reported improved relationships, while 30% feel theirs have worsened.

    • Sleep separation also impacts intimacy — 28% say their sex life has improved, while 22% report the opposite.

    Sleep Quality Isn't Equal Across Genders

    Women experience poorer sleep quality than men:

    • Women report fewer nights of quality sleep than men (3.83 nights vs. 4.13 nights) per week.
    • 38% of women struggle to fall asleep compared to 29% of men.
    • Hormonal changes—particularly menopause—are a significant but often overlooked factor affecting sleep, with 44% of menopausal women reporting difficulty falling asleep at least three times per week, compared to 33% of non-menopausal women.

    Take Action on Sleep Health

    "Chronic poor sleep impacts our relationships, workplace productivity, and increases the risk of cognitive decline, mood disorders, and serious health conditions like heart failure and stroke," added Dr. Nunez. "For individuals with untreated or poorly managed sleep apnea, these risks are even greater. That's why talking with a doctor about treating disrupted sleep is important."

    Are you getting enough sleep? Read the full 2025 Global Sleep Survey to learn more about the trends impacting the way we sleep. To assess your sleep health, take our sleep assessment.

    Survey Methodology

    ResMed commissioned a survey of 30,026 individuals in the United States (5,000), China (5,000), India (5,000), United Kingdom (2,000), Germany (2,004), France (2,001), Australia (1,501), Japan (1,500), Korea (1,500), Thailand (1,519), New Zealand (1,000), Singapore (1,000), and Hong Kong (1,001). The samples within each country were representative of the population's gender and age breakdowns. The survey was fielded by PureSpectrum from 12 to 28 December 2024.

    About ResMed

    At ResMed (NYSE:RMD, ASX: RMD)) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

    Contacts

    For media

    628-278-6471

    [email protected]

    For investors

    +1 858.836.5000

    [email protected]


    1 Routinely assessing patients' sleep health is time well spent, Jean-Philippe Chaput, Judy Shiau, Preventive Medicine Reports Volume 14, June 2019, 100851

    2 Gordon AM, Chen S. The role of sleep in interpersonal conflict: Do sleepless nights mean worse fights? Social Psychological and Personality Science. 2014;5(2):168–175



    Primary Logo

    Get the next $RMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    9/18/2025$330.00Buy
    Citigroup
    9/2/2025Hold → Outperform
    CLSA
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    1/16/2025Buy
    Goldman
    1/10/2025$252.00Neutral
    Piper Sandler
    More analyst ratings

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on ResMed with a new price target

    Citigroup initiated coverage of ResMed with a rating of Buy and set a new price target of $330.00

    9/18/25 8:44:39 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed upgraded by CLSA

    CLSA upgraded ResMed from Hold to Outperform

    9/2/25 11:05:47 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00

    7/16/25 7:50:57 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy

    SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Settings (PTCS), to be marketed as Smart Comfort. Smart Comfort is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings to help people with obstructive sleep apnea (OSA) start and stay on CPAP therapy. Smart Comfort will launch in early 2026 in a limited U.S. beta version for new users of myAir™, Resmed's consumer sleep companion app, paired with a Resmed AirSense™

    12/8/25 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

    Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended September 30, 2025. "Our fiscal year 2026 is off to a strong start, with first-quarter performance r

    10/30/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025

    SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location:https://investor.resmed.com •Date:Thursday, October 30, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Thursday, October 30, 2025, 8:30 p.m. GMTSydney, Friday, October 31, 2025, 7:30 a.m. AEDT     Please note,

    10/9/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,254,796 worth of ResMed Common Stock (4,991 units at $251.41) (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    12/9/25 3:17:15 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Director Farrell Peter C sold $502,940 worth of ResMed Common Stock (2,000 units at $251.47), decreasing direct ownership by 3% to 68,773 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    12/4/25 1:46:37 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Global General Counsel Rider Michael J sold $12,208 worth of ResMed Common Stock (50 units at $244.16), decreasing direct ownership by 0.51% to 9,791 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    12/2/25 4:27:35 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    SEC Filings

    View All

    SEC Form S-8 filed by ResMed Inc.

    S-8 - RESMED INC (0000943819) (Filer)

    11/21/25 1:17:30 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by ResMed Inc.

    S-8 - RESMED INC (0000943819) (Filer)

    11/21/25 1:08:30 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - RESMED INC (0000943819) (Filer)

    11/20/25 4:30:26 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

    NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

    2/4/25 9:15:00 AM ET
    $IXHL
    $RMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/23 1:36:52 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 5:05:17 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 8:32:59 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Financials

    Live finance-specific insights

    View All

    Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

    Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended September 30, 2025. "Our fiscal year 2026 is off to a strong start, with first-quarter performance r

    10/30/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025

    SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location:https://investor.resmed.com •Date:Thursday, October 30, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Thursday, October 30, 2025, 8:30 p.m. GMTSydney, Friday, October 31, 2025, 7:30 a.m. AEDT     Please note,

    10/9/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

    Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4

    7/31/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care